Ignite Creation Date:
2025-12-24 @ 9:43 PM
Ignite Modification Date:
2026-01-02 @ 9:32 AM
Study NCT ID:
NCT05936632
Status:
COMPLETED
Last Update Posted:
2024-06-11
First Post:
2023-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
Sponsor:
London School of Economics and Political Science
Organization:
Study Overview
Official Title:
Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.
It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.
This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.
To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.
This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.
To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: